Multi-Antibody SARS-CoV-2 Compositions for Variant Neutralization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing vaccines and antibody treatments for COVID-19 have reduced efficacy against emerging variants of SARS-CoV-2, necessitating the development of medicaments that can effectively prevent and treat infections caused by new variants.
Innovation Solution
Development of antibodies and antigen-binding fragments that specifically bind to the spike protein of SARS-CoV-2, including compositions and combinations of antibodies with defined CDR sequences, which neutralize various SARS-CoV-2 variants with high efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing vaccines and antibody treatments are used, then they provide protection against original SARS-CoV-2 strains, but their efficacy is reduced against emerging variants
Solution Approach 1:
The patent develops antibody compositions that can bind to multiple SARS-CoV-2 variants (including Alpha, Beta, Gamma, Delta, and Omicron) simultaneously. The selected antibodies target conserved regions of the spike protein that are less prone to mutation, enabling a single treatment to provide broad-spectrum protection against diverse viral strains rather than being strain-specific
Solution Approach 2:
The patent employs a systematic approach of screening and selecting antibodies with optimized binding characteristics. By measuring neutralization potency (IC50 values) against multiple variants and selecting antibodies that maintain high affinity across variants, the patent changes the parameter of antibody selection criteria from strain-specific optimization to cross-variant robustness, thereby resolving the contradiction between reliability and adaptability
2Ease of operation
If single antibody treatments are used, then they are simple to administer, but they may not provide sufficient neutralization against highly mutable viral targets
Solution Approach 1:
The patent combines multiple monoclonal antibodies into a single fixed-ratio composition (e.g., RQ33, RQ40, RQ41, and RQ43 in specific proportions). This merging approach maintains ease of administration as a single injection while achieving synergistic or additive neutralization effects that are greater than individual antibodies alone, particularly against variants with multiple spike protein mutations
Solution Approach 2:
The patent creates a composite antibody therapy where multiple distinct monoclonal antibodies with different epitope specificities are formulated together. Each antibody targets different regions or conformations of the spike protein, and their composite action provides more robust and reliable neutralization compared to single antibody treatments, while still being administered as a unified pharmaceutical composition
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibodies and antigen-binding fragments demonstrate potent neutralization of SARS-CoV-2 variants, including BA.2.12.1, with IC50 values of 25 ng/ml or less, and neutralize pseudoviruses with EC50 values of 100 ng/mL or less, providing effective prevention and treatment options.
Implementation Method 1
antibodies or antigen-binding fragments thereof that specifically bind to the spike protein of SARS-CoV-2
Data Source
AI summary
The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to the spike protein of SARS-CoV-2 and methods of making and using the same. The antibodies can be used, for example, in prophylaxis, post-exposure prophylaxis, or treatment of SARS-CoV-2 infection. The antibodies can also be used to detect SARS-CoV-2, e.g., an infection in subject.